Genentech, Inc.
$400.6M 2,544 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP reported $428,167,709.31 across General Payments, Research, and Ownership to 858,609 physicians and teaching hospitals across 864,383 transactions.
- $428.2M Top 1% payer
- All-tracks total
- 864,383 Top 1% volume
- Transactions
- 858,609 Top 1% reach
- Recipients
- +$7.5M
- General Payments vs PY2023
AstraZeneca Pharmaceuticals LP reported $428,167,709.31 across all CMS Open Payments tracks (General + Research + Ownership) to 858,609 physicians and teaching hospitals in Program Year 2024 - ranking #7 of 1,925 reporting manufacturers (3.1% of the all-tracks industry total); General Payments alone were $64,724,186.83, averaging $498.68 per recipient.
How AstraZeneca Pharmaceuticals LP's $428.2M all-tracks total breaks down
AstraZeneca Pharmaceuticals LP's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer astrazeneca-pharmaceuticals-lp AstraZeneca Pharmaceuticals LP
$428.2M · #7/1,925 · 3.1% industry · PY2024
- TOT $428.2M
- RANK #7
- SHARE 3.1%
- TXN 864,383
- RCP 858,609
- CAT 11
- GEN $64.7M
- ΔGEN +$7.5M
- TOP1 3.8%
- PY 2024
Volume peers
Nearest volume peer: Genentech, Inc. ($400.6M)
AstraZeneca Pharmaceuticals LP sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
AstraZeneca Pharmaceuticals LP's CMS-reported General Payments increased by $7.5M (+13.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ASTRAZENECA PHARMACEUTICALS LPPY2023: ASTRAZENECA PHARMACEUTICALS LPPY2024: AstraZeneca Pharmaceuticals LP. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $57,247,929.30
- PY2024
- $64,724,186.83
What the Data Shows for AstraZeneca Pharmaceuticals LP
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For AstraZeneca Pharmaceuticals LP, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 11-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $28.4M, accounting for 43.9% of this company's General Payments and 12,785 transactions.
General Payment Breakdown by Type
AstraZeneca Pharmaceuticals LP made 11 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $28.4M, 43.9% of General Payments.
AstraZeneca Pharmaceuticals LP reports 11 general-payment categories - the top three are Compensation for Services Other Than Consulting (43.9%), Food and Beverage (26.9%), and Consulting Fee (14.7%). The remaining 8 categories make up 14.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: AstraZeneca Pharmaceuticals LP files across 11 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How AstraZeneca Pharmaceuticals LP divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $28.4M | 12,785 | 43.9% |
| Food and Beverage | $17.4M | 824,499 | 26.9% |
| Consulting Fee | $9.5M | 4,937 | 14.7% |
| Grant | $4.3M | 220 | 6.6% |
| Travel and Lodging | $3.3M | 10,541 | 5.1% |
| Space Rental or Facility Fees | $1.4M | 615 | 2.1% |
| Gift | $187.0K | 11 | 0.3% |
| Education | $113.3K | 4,747 | 0.2% |
| Royalty or License | $92.5K | 1 | 0.1% |
| Compensation for Faculty or Speaker (Medical Education) | $56.0K | 130 | 0.1% |
| Charitable Contribution | $38.1K | 123 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,731,100.52 (5.8%) of $64,724,186.83 in this company's General Payments records across 138,305 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for AstraZeneca Pharmaceuticals LP
The five named recipients with the highest reported General Payments from this company
- 1
National Jewish Health
$2,428,146.00 across 18 reported transactions
- 2
Howard University Hospital
$387,650.00 across 4 reported transactions
- 3
Ohsu Hospital And Clinics
$376,360.00 across 7 reported transactions
- 4
Emory University Hospital
$278,944.52 across 14 reported transactions
- 5
Tufts Medical Center
$260,000.00 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
AstraZeneca Pharmaceuticals LP ranks #7 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,810 of 1,838 by HHI (bottom 2% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Revance Therapeutics, Inc. : $1.2M total payments, HHI 24
- Alvogen Inc : $19.0K total payments, HHI 24
- OptumHealth Care Solutions, LLC : $44.5K total payments, HHI 24
- Medical Device Business Services, Inc. : $24.4M total payments, HHI 24
- Abbott Laboratories : $38.3M total payments, HHI 23
- ABC Home Medical Supply, Inc. : $21.4K total payments, HHI 22
- AstraZeneca Pharmaceuticals LP (this company) : $64.7M total payments, HHI 22
- Forte Bio-Pharma LLC : $118.4K total payments, HHI 22
- Pfizer Inc. : $43.5M total payments, HHI 22
- Orexo US, Inc. : $36.3K total payments, HHI 20
- Genentech USA, Inc. : $8.5M total payments, HHI 20
- Seagen Inc. : $52.4K total payments, HHI 20
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as AstraZeneca Pharmaceuticals LP's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about AstraZeneca Pharmaceuticals LP.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with AstraZeneca Pharmaceuticals LP.
Showing 6 of 1,924 companies with CMS-reported payment data.
Midmark Corporation
$386.1M 378 recipients
Compare payment profiles
Janssen Research & Development, LLC
$345.1M 1,588 recipients
Compare payment profiles
Amgen Inc.
$343.0M 474,864 recipients
Compare payment profiles
Merck Sharp & Dohme LLC
$525.2M 216,602 recipients
Compare payment profiles
E.R. Squibb & Sons, L.L.C.
$251.5M 236,558 recipients
Compare payment profiles
Put this to use
AstraZeneca Pharmaceuticals LP ranks #7 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where AstraZeneca Pharmaceuticals LP sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just AstraZeneca Pharmaceuticals LP. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.